Search clinical trials for: NS2 Ophthalmic Drops Vehicle (0.0%)

Total 1252 results

Aldeyra Therapeutics, Inc.

Completed

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis | Seasonal Allergies

Canada
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Allgenesis Biotherapeutics Inc.

Completed

A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia (SURPH)

Pterygium

Australia
Silk Technologies, Ltd.

Completed

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS201)

Dry Eye

United States
Aurinia Pharmaceuticals Inc.

Completed

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome (AUDREY)

Keratoconjunctivitis Sicca | Dry Eye Syndrome

United States
Xequel Bio, Inc.
United States Department of Defense

Completed

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

Dry Eye Disease

United States
Santen Inc.
ActualEyes Inc.

Recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States
Ospedale San Raffaele
Dompé Farmaceutici S.p.A

Completed

Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema (NEMO)

Retinitis Pigmentosa | Cystoid Macular Edema

Italy
Amorepacific Corporation

Completed

Cumulative Irritation Test of PAC-14028 in Healthy Volunteers

Healthy

Korea, Republic of
Alcon Research

Withdrawn

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis
Seinda Pharmaceutical Guangzhou Corporation

Completed

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
VivaVision Biotech, Inc

Recruiting

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Inflammation

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR8028 Eye Drops for the Treatment of Dry Eye Disease

Dry Eye Disease

China
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Alcon Research

Completed

Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects

Dry Eye

India
Allysta Pharmaceutical

Completed

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
VivaVision Biotech, Inc

Completed

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Glaucoma, Open-Angle

United States
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Alcon Research

Completed

A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye

Dry Eye
Michigan Cornea Consultants, PC
Kresge Eye Institute

Completed

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

Dry Eye | Sjogren's Syndrome | Graft vs. Host Disease

United States
Democritus University of Thrace
George Papanicolaou Hospital; Naval Hospital, Athens; Athinaiki General Clinic

Completed

Impact of 0.1% and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Phacoemulsification Surgery

Cataract

Greece
Aldeyra Therapeutics, Inc.

Completed

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

Sjögren-Larsson Syndrome

United States
Allergan

Completed

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Amorepacific Corporation
Seoul National University Hospital

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male Subjects

Healthy

Korea, Republic of
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)

Ocular Infections, Irritations and Inflammations

United States
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Novaliq GmbH

Completed

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Dry Eye Disease

United States
Rigel Pharmaceuticals

Completed

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Allergan

Completed

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma, Open-Angle

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Novaliq GmbH

Completed

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Dry Eye Disease

United States
Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
SIFI SpA

Completed

Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis

Acanthamoeba Keratitis

Italy, United Kingdom, Poland
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Azura Ophthalmics
ORA, Inc.

Not yet recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Dry Eye Disease

United States
Silk Technologies, Ltd.

Completed

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

Dry Eye

United States
Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Aldeyra Therapeutics, Inc.

Completed

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Non-infectious Anterior Uveitis

United States
Alcon Research

Completed

Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects

Dry Eye
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States

3

Subscribe